<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550145</url>
  </required_header>
  <id_info>
    <org_study_id>29010</org_study_id>
    <nct_id>NCT02550145</nct_id>
  </id_info>
  <brief_title>Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery</brief_title>
  <official_title>The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracey McLaughlin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial
      glucose reductions after bariatric surgery in a subset of patients who have severe
      symptomatic hypoglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The physiologic mechanisms mediating the glucose-lowering effect of Roux-en-Y Gastric Bypass
      (RYGB) or post-Vertical Sleeve Gastrectomy (VSG) are unknown. The reduction in glucose
      excursions prior to weight loss has lead to postulates that the incretin hormone, GLP-1, may
      play an important role.

      The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial
      glucose reductions in a subset of post-bariatric patients through the pharmacologic blockade
      of the GLP-1 receptor in post-RYGB or post-VSG patients with severe symptomatic hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucose area under the curve</measure>
    <time_frame>0 to 180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin area under the curve</measure>
    <time_frame>0 to 180 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypoglycemia symptom score</measure>
    <time_frame>0-180 minutes</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Exendin(9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of Exendin (9-39).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin (9-39)</intervention_name>
    <description>IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).</description>
    <arm_group_label>Exendin(9-39)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-65

          -  BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric
             surgery

        Exclusion Criteria:

          -  Acute medical illness, such as acute bacterial or viral syndrome, febrile illness,
             acute abdominal symptoms, orthopedic injury within one week

          -  History of cardiac failure, renal insufficiency (estimated Crcl&lt;30cc/min), hepatic
             insufficiency, chronic obstructive pulmonary disease, anemia (Hct&lt;30%), or
             uncontrolled hypertension (SBP&gt;160 or DBP&gt;100)

          -  Pregnancy

          -  Use of medications that affect glucose metabolism

          -  Fasting glucose &gt;150 or HbA1c&gt;7.5 on Metformin

          -  Women of childbearing potential (will have a pregnancy test, in addition use of
             abstinence for at least one month prior to study or use two types of contraceptives,
             hormonal implant or Depo Provera)

          -  Active, uncontrolled psychiatric disease

          -  Participating in other studies or have received investigational medications within the
             past month or 5 half-lives of the drug, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Craig, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Craig, M.D.</last_name>
    <phone>650-736-2056</phone>
    <email>cmcraig@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracey McLaughlin, M.D.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Craig, M.D.</last_name>
      <phone>650-350-2153</phone>
      <email>cmcraig@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Tracey McLaughlin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperinsulinemic</keyword>
  <keyword>post-bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

